Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 in Agitation Associated With Schizophrenia
NCT04010305Phase 1Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexmedetomidine in agitation (5 arms), sponsored by BioXcel Therapeutics, Inc. Primary endpoint: Positive and Negative Syndrome Scale - Excited Component Change From Baseline at 120 months. Started May 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT04010305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04010305.